Clinical trial · no report yet · Phase 2
ADEPPT
Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status
- NCT05673187 ↗
- Active, not recruiting
- ETOP IBCSG Partners Foundation
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Multicentre, Single-arm Phase II Trial of Adagrasib in Patients With KRASG12C-mutant NSCLC, Including the Elderly (≥70 Years) or Patients With Poor Performance Status
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- NSCLC Stage IV; KRAS P.G12C
- Interventions
- Adagrasib
- Arms
- Treatment Arm · Experimental
- Enrollment
- 68 (estimated)
- Primary outcomes
- Objective Response Rate (ORR) per RECIST v1.1, assessed at 12 weeks.
- Sponsor
- ETOP IBCSG Partners Foundation with Mirati Therapeutics Inc.
- Start
- Jun 12, 2023
- Primary completion
- Jul 28, 2025
- Results posted
- No
- Registry record
- NCT05673187 · updated Sep 3, 2026